BIOLIFE SOLUTIONS INC — Director's Dealing 2020

Mar 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2020-03-04

Reporting Person: DE GREEF RODERICK (CFO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-04	Common Stock	M	10000	$1.81	Acquired	35859	Direct
2020-03-04	Common Stock	S	10000	$13.95	Disposed	25859	Direct
2020-03-05	Common Stock	M	10000	$1.81	Acquired	35859	Direct
2020-03-05	Common Stock	S	10000	$13.72	Disposed	25859	Direct
2020-03-06	Common Stock	M	10000	$1.81	Acquired	35859	Direct
2020-03-06	Common Stock	S	10000	$13.77	Disposed	25859	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-04	Employee Stock Option	$1.8099	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct
2020-03-05	Employee Stock Option	$1.8099	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct
2020-03-06	Employee Stock Option	$1.8099	M	10000	Disposed	2026-05-03	Common Stock (10000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option	$1.7600	2026-03-04	Common Stock (30000)	30000	Direct
Employee Stock Option	$1.6400	2021-12-20	Common Stock (6919)	6919	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.85 to $14.01 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.60 to $14.00 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

F5: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues.